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Abstract
Background: The use of specific drugs to facilitate, enhance or prolong sexual sessions is referred to as ‘chemsex’.
The popularity of the behavior seems to be growing, but there is a paucity of information on the mental health
aspects associated with chemsex and no data on chemsex from Nordic countries. We investigated the link between
chemsex and mental health among men who have sex with men (MSM) and other men in Norway.
Methods: We recruited participants from a walk-in sexually transmitted infections (STI) clinic. Participants completed
a piloted, anonymous self-administered survey. It consisted of questions about men’s sociodemographic
characteristics, mental health, sexual behaviors, substance use, and chemsex. The outcome we investigated was
reduced mental health, measured with the validated Hopkins Symptom Check List. We obtained descriptive
statistics and performed univariate and multivariate logistic regression analyses.
Results: 1013 (96%) of the surveys were complete and could be analysed. The mean age of the sample was 33,
51% were MSM, and 21.7% had reduced mental health. More MSM than other men engaged in chemsex in the
past year (17% vs 12%). The most frequently reported chemsex drugs were cocaine and gamma hydroxybutyrate/
gamma butyrolactone (GHB/GBL). Men engaged in chemsex primarily to enhance sexual pleasure and excitement,
and about half reported almost never or never using condoms for chemsex. In univariate analyses, significant
predictors of reduced mental health was chemsex (Odds Ratio [OR] = 1.82), being unemployed (OR = 3.54), and
having sex with only women (OR = 0.58). In multivariate analyses, two variables remained significantly associated
with reduced mental health: chemsex (adjusted OR = 2.18, 95%CI = 1.25–3.78) and being unemployed (adjusted
OR = 4.10, 95%CI = 2.13–7.87).
Conclusions: In our sample of men from an STI clinic in Norway, about 14% self-reported engaging in chemsex in
the past year and about a fifth of the men had reduced mental health. Men who engaged in chemsex, which more
MSM engaged in than other men, had two times greater odds of reduced mental health. These findings suggest
that mental health assistance should be among the interventions offered to men engaging in chemsex.
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Background
The use of recreational substances for sex is not a new
phenomenon. Sex while intoxicated or high occurs in
both men and women and across sexual orientations, al-
though there is mounting evidence that such drug use is
more common among sexual minorities [1, 2]. These
days, according to a global drug survey, the most com-
monly used drugs with sex are alcohol, cannabis, and
MDMA (methylenedioxymethamphetamine) [1]. Re-
cently, the use of specific recreational drugs to facilitate,
enhance or prolong sexual sessions is increasingly re-
ferred to as ‘chemsex’ [3, 4]. The drugs most commonly
used are methamphetamines, gamma hydroxybutyrate/
gamma butyrolactone (GHB/GBL), mephedrone, co-
caine, and ketamine [4, 5]. Although there is limited sys-
tematic data available, existing scholarship shows that
while such substances are used with sex by both men
having sex with men (MSM) and men having sex with
women, chemsex is considerably more common among
MSM than other men. Lawn and colleagues [1] found
that more MSM than non-MSM used cocaine, GHB/
GBL, ketamine, mephedrone, and methamphetamine
with sex. Use in the past 12 months among MSM varied
from 4.2% (mephedrone) to 14.1% (cocaine) and among
non-MSM from 0.7% (GHB/GBL) to 10.1% (cocaine).
Also a review of chemsex shows that prevalence
estimates of chemsex among MSM vary greatly across
various samples and measurement and recruitment
methods used, ranging from 3 to 29% [4]. Longitudinal
research demonstrates mixed evidence on prevalence
changes over time in the use of chemsex drugs among
MSM [6, 7].
Chemsex has been enabled by the last decade’s geospa-
tial networking applications such as Grindr and other
online sites to meet sexual partners [3], but there are
also underlying physical, emotional, and social drivers
for engaging in chemsex. These appear to be complex,
but there are indications that those who engage in
chemsex are seeking a powerful sexual experience. The
typical chemsex drugs are stimulants that provide feel-
ings of euphoria, heightened sexual arousal, and in-
creased stamina which facilitate long sexual sessions
with multiple partners [4, 8, 9]. Qualitative interviews
suggest that reasons for engagement in chemsex include
not just the enhanced sexual and physical sensations
[10], but also cognitive disengagement, intensified per-
ceptions of intimacy, and overcoming social inhibitions
as well as stigma, marginalisation, and minority stress
[10, 11]. Pollard and colleagues [11] highlight how
chemsex, as an individual and social behavior, exists
within syndemics of marginalisation and health inequal-
ity. They point to research such as those by Berg and
colleagues [12, 13], showing that an insidious conse-
quence of heteronormativity and minority stress is the
internalisation of that stigma by sexual minorities, mani-
fest as e.g. internalised homonegativity, which in turn is
a predisposing factor in several aspects of ill health, such
as loneliness. Research has revealed that syndemics of
marginalisation of gay, bisexual, and other MSM are so-
cial determinants of health challenges like HIV-risk,
mental health burdens, illicit drug use, and sexual risk
taking [2, 11]. In this conceptualisation, chemsex and its
social context are mutually constituted [11].
While the use of ‘chem’-drugs, regardless of who con-
sumes them, can have serious implications for those tak-
ing them because of the direct negative effects of the
drugs themselves [14, 15], there are also inter-connected
risk behaviors associated with combining chem-drugs
and sex. Two recent literature reviews [4, 16] concluded
that MSM who engage in chemsex are more likely than
men who do not engage in chemsex to engage in con-
domless anal intercourse, perform esoteric sex acts such
as fisting and group sex, and to be diagnosed with sexu-
ally transmitted infections (STIs) and HIV. The rise of
chemsex as a public health issue may be due to its asso-
ciated sexual risk-taking, but there are also issues around
sexual consent, difficulties in negotiating sex [3], de-
struction of social and romantic relationships, and
chemsex as a maladaptive coping strategy for painful
emotions [11].
While there appears to be generous research on the
association between chemsex and physical health, such
as STIs, the authors of the literature reviews of chemsex
related behaviors [4, 16] identified only a handful of
studies on the psychosocial impacts of chemsex. Overall,
these studies from the UK, USA and Australia suggested
that chemsex drug use negatively affected men’s lives,
including employment, social networks, and daily func-
tioning. For example, two studies from sexual health
clinics in London identified that 15 and 42% of the
MSM respondents, respectively, perceived chemsex to
have an adverse impact on their mental health [17, 18].
A US-based study, with focus groups of 15 MSM, re-
corded experiences of paranoia, short-term depression,
and psychosis following chemsex engagement [19].
However, none of these studies examined the statistical
association between chemsex and mental health. This
knowledge gap is recently beginning to be addressed,
notably by three UK-based studies. First, both a national
probability sample among sexually active HIV-positive
MSM and a sample of HIV-negative MSM, recruited
from sexual health clinics, found that chemsex was asso-
ciated with self-reported ever diagnosis of depression or
anxiety [20] and symptoms of depression and anxiety
[7]. However, the associations were not significant once
other factors were controlled for. Similarly, while an on-
line survey found that sexualised drug use – which in-
cluded use of substances such as alcohol and erectile
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dysfunction drugs just before or during sex – was corre-
lated with lower satisfaction with life, the multivariate
analyses showed no significant differences in psycho-
logical distress, internalised homonegativity, loneliness,
or satisfaction with life between MSM engaging in sex-
ualised drug use and MSM engaging in chemsex [9]. In
another UK-based study, chemsex drug use (which does
not necessarily equate to engaging in chemsex) was asso-
ciated with symptoms of depression [21].
Although there appears to exist few studies on chem-
sex from Nordic countries [4, 16], we identified a recent
cross-sectional study from 13 European cities, including
the capital of Sweden, which examined the prevalence
and predictors of drug use during the last sexual en-
counter [22]. It found that 3.4% of the 4266 MSM re-
spondents reported the use of chemsex drugs (GHB/
GBL, ketamine, mephedrone, crystal methamphetamine)
during last anal sex with a male partner. Prevalence
across the 13 cities ranged from 0 to 13.9%, with only
one man residing in Stockholm reporting such use.
Chemsex was strongly associated with recent STI diag-
nosis, younger age, history of injecting drug use, and
sexual encounters with more than one partner. It bears
mention that one older Internet-based study among
MSM from Norway found that 10% reported being
under the influence of selected drugs during sex in the
past year, and the behavior was associated with being
diagnosed with HIV. However, the drugs were not spe-
cifically chemsex drugs, rather included marihuana, pre-
scription drugs, ecstasy, LSD, GHB, cocaine, heroin,
amphetamines, and methamphetamines [23].
It is clear that the use of chemsex drugs and chemsex
vary greatly across cities and sub-groups, partially be-
cause laws and social attitudes to drugs are likely to in-
fluence use and that the concept of chemsex is socially
constructed. To date, there are limited data on chemsex
among non-MSM, men residing in Nordic countries,
and the link between chemsex and mental health. Thus,
given growing international evidence of the popularity of
chemsex, the potential risks associated with the use, the
limited data on the mental health aspects, and the pau-
city of information on this issue in Nordic countries, we
investigated the link between chemsex and mental health
among MSM and other men attending a sexual health
clinic in Norway.
Methods
The methods are reported according to the STROBE
guidelines for observational studies [24]. Study proce-
dures were reviewed and approved by the Regional
Committee for Medical and Health Research Ethics, re-
gion south east Norway. The Data Protection Impact
Assessment was approved through the Oslo University
Hospital.
Study population
We recruited participants from a walk-in STI clinic in
Norway. Eligibility criteria were: (1) being over 16 years
(age of consent); (2) birth-assigned male sex; (3) had sex
in the last year; (4) being able to read Norwegian or
English.
Recruitment and procedures
Recruitment occurred between July and October 2016 at
the largest STI clinic in Norway (Olafiaklinikken), in
Oslo. It is a low-threshold – most services are free of
charge – drop-in clinic for the diagnosis and treatment
of STIs. The receptionists informed male patients about
the study. Eligible men who expressed interest were
asked to complete the paper-and-pencil survey and sub-
sequently place it in a locked box located in the waiting
room. The survey was available in English and Norwe-
gian. It took 5–10min to complete. All data collected
were anonymous.
Measures
We piloted the first version of the survey, which was
specifically developed for this study, with 20 patients
(not included in the final dataset). They provided de-
tailed feedback on the contents, functionality, and survey
layout. After revisions, the final survey comprised 48
questions that fit on two sheets of paper (supplementary
file 1). We used the validated Hopkins Symptom Check
List (HSCL-10) to assess mental health, the dependent
variable. It has high reliability (Cronbach’s alpha = 0.88),
high validity (89% sensitivity, 98% specificity), behaves in
the same way in different socio-demographic groups
(e.g. age, gender, level of education, employment), and
shows high correlation with similar instruments (0.91–
0.97), which indicates that the same characteristics are
measured [25]. Reliability in the current sample was
0.91. HSCL-10 consists of 10 symptoms of distress (de-
pression and anxiety) that people may have experienced
in the last 2 weeks. Respondents were asked to assess
each item using a 4-point Likert scale ranging from 1 =
“Not at all”, 2 = “A little”, 3 = “Quite a bit”, to 4 = “Ex-
tremely”. The average score is calculated by dividing the
total score by the number of items, with a theoretical
range of 1–4, and a reduced mental health cutoff ≥1.85
[25]. Another five single items probed further details of
mental health, including suicidal thoughts.
With respect to the other variables, we asked about
sociodemographic characteristics, sexual orientation and
behaviors, STI/HIV history and testing, and substance
use. These were adapted from research on similar topics
[26]. We had 15 questions about chemsex, with the
wording for chemsex, the independent variable of inter-
est, being “In the last 12 months, how often have you
taken drugs immediately preceding and/or during the
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sexual session (i.e., engaged in ‘chemsex’)? Drugs include
methamphetamine, GHB/GBL, mephedrone, ketamine,
cocaine”. We used the term chemsex in both Norwegian
and English. We specified the five drugs in accordance
with existing evidence [5].
Statistical analyses
SPSS 23.0 statistical software was used to perform ana-
lyses. We used descriptive statistics to examine sample
characteristics and proportions with reduced mental
health. To examine differences between MSM and non-
MSM we used Chi-square tests. We conducted first uni-
variate analyses and next a multivariate analysis using lo-
gistic regression with reduced mental health as outcome
variable. We used the enter method with intercept, in-
cluding eight explanatory variables that met collinearity
requirements. Analyses were two-tailed with significance
set at the 5% level.
Results
Of the 1050 surveys handed out, 1013 (96%) were
complete and could be analysed. As shown in Table 1,
the mean age of the sample was 33, three quarters had a
university degree and worked full- or part-time, and 60%
described themselves as single. Half of the sample self-
described as gay or bisexual, and a little more than half
of the sample (50.7%) self-reported having sex with men
in the past year (MSM). For this study, MSM are defined
as men who self-reported having sex with men in the
past year. Nine of ten respondents had lived in Norway
for more than ten years. Not shown is that 44 (4.3%)
self-reported living with HIV (all except one man was
MSM). Further details of the sample are available in a
separate Norwegian report [27].
With respect to mental health, our outcome of inter-
est, we found that 21.7% of the sample had reduced
mental health (score ≥ 1.85 on symptoms of depression
and anxiety). Moreover, 9% were currently receiving
therapy from a psychologist or psychiatrist, 2.7% had at-
tention deficit hyperactivity disorder, and in the past
year 3.3% had seriously considered suicide, 0.5% had
attempted suicide, and 0.4% had been admitted to a psy-
chiatric ward. With regard to these five variables, there
was no statistically significant difference between those
who engaged in chemsex and those who did not (p =
0.94, 0.15, 0.13, 0.99, 0.99, respectively).
Description of chemsex experiences
All but 12 men (n = 1001) answered the questions about
chemsex, of which 144 (14.4%) reported having engaged
in chemsex in the past year. Table 2 shows the charac-
teristics of chemsex use among these men. Three quar-
ters of men reporting chemsex in the past year had
engaged in chemsex two or more times, and the most
frequently reported chemsex drugs were cocaine and
GHB/GBL. They engaged in chemsex primarily to en-
hance sexual pleasure (57%), excitement (47%), and abil-
ity (24%). The location for the activity was largely in a
private home (73%) and about half reported almost
never or never using condoms. About one in ten had a
few times experienced physical problems or psycho-
logical problems related to chemsex, and two in ten had
engaged in activities during chemsex that they regretted.
13% stated they had ever wanted to quit chemsex.
Slightly more MSM than other men engaged in chemsex
(17% vs 12%). Significantly more MSM than non-MSM
used GHB/GBL, engaged in chemsex to enhance sexual
pleasure and excitement, found partners via the Internet
or App or sauna, and had chemsex in private homes,
sauna or sex clubs. Not shown is that more MSM also
had a higher number of sex partners and more STIs.
One man reported having been hospitalised for medical
issues caused by chemsex, six reported ‘slamming’
(injecting drugs) and one sharing of needles in relation
to chemsex.
Association between reduced mental health and selected
variables
As seen in Table 3, in univariate analyses, significant
predictors of reduced mental health were chemsex (odds
ratio [OR] = 1.82), being unemployed (OR = 3.54), and
having sex with only women (OR = 0.58). In the multi-
variate analysis, two variables remained significantly as-
sociated with reduced mental health: chemsex (adjusted
OR = 2.18, 95%CI = 1.25–3.78) and being unemployed
(adjusted OR = 4.10, 95%CI = 2.13–7.87).
Discussion
This is the first study from a Nordic country to demon-
strate that chemsex occurs among both MSM and non-
MSM and is associated with reduced mental health.
While several studies show that use of drugs is more
common among MSM than non-MSM [6, 28, 29], we
are only aware of one other study with both MSM and
non-MSM that has examined the use of specific recre-
ational drugs used shortly before the sexual session [1].
Similar to the study by Lawn and colleagues [1], we
found that chemsex was somewhat more common
among MSM (17% vs 12%), they were more likely to
prefer GHB/GBL and used the drugs to enhance the sex-
ual experience. MSM differed from non-MSM also in
means of finding chemsex partners and location of hav-
ing chemsex, relying more on Apps and private homes.
Otherwise, there were surprisingly few differences and
more research is encouraged to continue to explore
potential differences in the phenomenon of chemsex
between the two groups.
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In our sample of 1013 men from a walk-in STI clinic
in Norway, about a fifth of the men had reduced mental
health. The rate was similar between MSM and non-
MSM (22.6% vs 19.0%). Relative to three other clinic-
based studies on chemsex, this is higher than the rate of
clinically significant depressive or anxiety symptoms [7],
similar to the rate of psychological distress [9], but lower
than the rate of ever being diagnosed with depression or
anxiety [20]. The modest differences are likely partly ex-
plained by differences in measurement methods used.
Related, in the past year, 3.3% had seriously considered
suicide and 0.5% had attempted suicide. While suicidal
thoughts and attempts signal reduced mental health,
these outcomes were not statistically associated with
chemsex (but reduced mental health was), possibly due
to the low numbers reporting such problems and this
being associated with other factors. Without doubt, from
a public health standpoint, these data on mental health
are worrying, as mental health problems is one of the
leading causes for loss of productivity and lower quality
of life. Some research shows that MSM experience
higher rates of mental health problems compared with
other men [30], and that people living with HIV are at
increased risk of mental health problems [31]. Our ana-
lysis from an STI clinic found that neither MSM nor
HIV-positive men were more likely than other men to
report symptoms of depression and anxiety. This is simi-
lar to recent UK-based research [9, 18]. Yet, we note that
meta-analyses of population-based studies have con-
cluded that the lifetime prevalence of suicide attempts in
gay/bisexual males is two to four times that of compar-
able heterosexual males [32].
Table 1 Sociodemographic characteristics of the sample and subgroups
Full sample
(N = 1013) %
Chemsex
(n = 144) %
No chemsex
(n = 857) %
Age (Mean [SD], range) 33.2 (9.2), 18–79 33.0 (8.0), 20–55 33.2 (9.4), 18–79
Current residency
Oslo 936 (92.8) 138 (95.8) 784 (91.5)
Elsewhere 73 (7.3) 5 (3.5) 69 (8.1)
Education
Primary school 26 (2.6) 4 (2.8) 20 (2.3)
High school/Secondary school 229 (22.6) 39 (27.1) 188 (21.9)
College/University degree 477 (47.1) 68 (47.2) 401 (46.8)
Master or Ph.D 280 (27.6) 32 (22.2) 246 (28.7)
Employment
Work full- or part time 758 (74.7) 107 (74.3) 642 (74.9)
Student 179 (17.6) 24 (16.7) 152 (17.7)
Unemployed 50 (4.9) 12 (8.3) 37 (4.3)
Retired/On disability/Other 28 (2.8) 1 (0.7) 26 (3.0)
Relationship status
In relationship with man 186 (18.4) 35 (24.3) 149 (17.4)
In relationship with woman 213 (21.0) 21 (14.6) 185 (21.6)
Single 605 (59.8) 88 (61.1) 512 (59.7)
Other 8 (0.8) 0 8 (0.9)
Sexual orientation
Gay/homosexual 438 (43.4) 74 (51.4) 361 (42.1)
Bisexual 71 (7.0) 12 (8.3) 58 (6.8)
Heterosexual 496 (49.2) 58 (40.3) 430 (50.2)
Other 4 (0.4) 0 4 (0.5)
Years lived in Norway
< 5 years 59 (6) 9 (6) 50 (6)
5–10 years 65 (6) 14 (19) 51 (6)
> 10 years 882 (87) 121 (84) 761 (89)
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Test for stat. Diff
Frequency of chemsex p = 0.35
Once 36 (25) 19 (22) 17 (30)
Two or more times 108 (75) 68 (78) 40 (70)
Drugs used for chemsex 1
Cocaine 90 (63) 45 (52) 45 (79) p = 0.22
GHB/GBL 41 (29) 37 (43) 4 (7) p = 0.001*
Methamphetamine 24 (17) 20 (23) 4 (7) p = 0.11
Ketamine 16 (11) 9 (10) 7 (12) p = 0.28
Mephedrone 9 (6) 8 (9) 1 (2) p = 0.05
Reasons for engaging in chemsex 1
Increased sexual pleasure 82 (57) 57 (66) 25 (44) p = 0.006*
Increased sexual excitement 67 (47) 46 (53) 21 (37) p = 0.017*
Increased sexual performance 34 (24) 22 (25) 12 (21) p = 0.78
Low self-esteem 8 (6) 5 (6) 3 (5) p = 0.87
Pressure from partner 5 (3) 4 (5) 1 (2) p = 0.35
Other 28 (19) 9 (10) 19 (33) p = 0.001*
Means/location of finding chemsex partner 1
Internet/App 52 (36) 49 (56) 3 (5) p = 0.001*
Sauna 6 (4) 6 (7) 0 p = 0.042*
Sex-club 7 (5) 5 (6) 2 (4) p = 0.52
Cruising place 4 (3) 2 (2) 2 (4) p = 0.69
Other 68 (47) 26 (30) 32 (56) p = 0.22
Location/place for chemsex 1
Private home 105 (73) 68 (78) 37 (65) p = 0.043*
Sexparty in private home 29 (20) 28 (32) 1 (2) p = 0.001*
Hotel 30 (21) 21 (24) 9 (16) p = 0.38
Sauna 9 (6) 9 (10) 0 p = 0.011*
Sexclub 8 (6) 8 (9) 0 p = 0.017*
Cruising place 3 (2) 2 (2) 1 (2) p = 0.80
Other 7 (5) 1 (1) 6 (11) p = 0.012*
Used condoms during chemsex p = 0.06
Almost never/never 67 (47) 37 (43) 30 (53)
A few times 16 (11) 11 (13) 5 (9)
Almost always/always 38 (26) 31 (36) 7 (12)
Had physical problems because of chemsex p = 0.76
Almost never/never 103 (72) 67 (77) 36 (63)
A few times 13 (9) 9 (10) 4 (7)
Almost always/always 5 (3) 4 (5) 1 (2)
Had psychological problems because of chemsex p = 0.81
Almost never/never 100 (87) 66 (76) 34 (60)
A few times 15 (10) 11 (13) 4 (7)
Almost always/always 5 (3) 3 (3) 1 (2)
Engaged in sexual activities during chemsex that you later regretted p = 0.57
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We found that reduced mental health was independ-
ently associated with engaging in chemsex and being
unemployed. To the best of our knowledge, and as indi-
cated by reviews about use of drugs for sexual purposes
[4, 16], our study is one of few to evaluate the independ-
ent association between chemsex and mental health.
This association was robust when potentially confound-
ing factors were controlled for. Our finding is confirma-
tory of other qualitative and quantitative research on
gay, bisexual and other MSM that has described detri-
mental consequences of chemsex on mental health [7,
17–20, 33, 34]. MSM respondents in both the UK and
US report adverse mental health effects, such as short
term depression and paranoia, following chemsex en-
gagement [17–19], and cross-sectional findings have
linked chemsex with symptoms of depression and anx-
iety, although not in multivariate analyses [7, 20]. The
most comprehensive assessment of aspects of chemsex
users’ psychological wellbeing to date [9], concluded that
chemsex users were more likely to report their sexua-
lised drug use having a negative impact on their life.
However, an examination of Australian MSM who used
GHB explicitly to enhance sexual experiences, often for
intensive sex partying, established no correlation be-
tween GHB and anxiety or depression [35]. Thus, there
is mixed research on the psychosocial impacts of chem-
sex, the existing studies’ design precludes assessment of
the causal direction of the association, and further
research with longitudinal designs are warranted. None-
theless, ours and others’ findings highlight a link be-
tween chemsex and MSM’s psychological wellbeing and
we encourage consideration of a syndemic perspective,
as suggested by e.g. Halkitis and colleagues [2], whereby
mental health, drug use, and STI and HIV transmission
risks are overlapping and synergistic health challenges,
partly driven by the psychosocial vulnerabilities experi-
enced by gay, bisexual and other MSM as sexual
minorities.
Taken together, while not all chemsex is problematic
in nature, our descriptive findings provide evidence that
mirrors previous research on disconcerting health conse-
quences from chemsex. For the large majority of our re-
spondents, chemsex was not a one-time occurrence and
research shows that drug use that is dependent or more
frequent has more detrimental impacts on people’s psy-
chosocial wellbeing [4]. In concert with other studies on
chemsex [4, 9, 16], about half of our respondents re-
ported almost never or never using condoms during
chemsex, 10–20% had experienced physical or psycho-
logical problems related to chemsex and had engaged in
activities during chemsex that they regretted. Thus,
these men are at risk of not only accidental overdose, ac-
quisition of STIs, HIV, and Hepatitis, but, as also other
researchers have found [3, 9, 14], doing things during
chemsex that they would not do when sober. Related, as
most research on chemsex has observed, the underlying







Test for stat. Diff
Yes 27 (19) 19 (22) 8 (14)
No 70 (49) 45 (52) 25 (44)
Unsure/Can’t remember 22 (15) 14 (16) 8 (14)
Wish to stop engaging in chemsex p = 0.97
Yes 18 (13) 13 (15) 5 (9)
No 53 (37) 37 (43) 16 (28)
Unsure 49 (34) 28 (32) 21 (37)
Legend: 1 = respondents could check more than one answer. * = p < 0.05
Table 3 Bivariate and multivariable logistic regression analysis of influence of chemsex on reduced mental health
Variable OR (95% CI) β (SE) aOR (95% CI)
Chemsex 1.82 (1.19–2.76) 0.78 (0.28) 2.18 (1.26–3.79) **
Age 0.99 (0.98–1.01) −0.01 (0.01) 0.99 (0.97–1.02)
HIV-positive 0.70 (0.30–1.61) −0.65 (0.55) 0.52 (0.18–1.54)
Unemployed 3.54 (2.09–6.00) 1.41 (0.33) 4.10 (2.14–7.88) **
Years lived in Norway 0.82 (0.46–1.48) −0.44 (0.37) 0.64 (0.31–1.32)
Steady relationship 1.16 (0.84–1.60) −0.05 (0.22) 0.95 (0.62–1.47)
Sex with only women 0.58 (0.35–0.96) −0.06 (0.35) 0.94 (0.48–1.87)
Used Internet to find sexual partners 0.94 (0.64–1.38) −0.02 (0.25) 0.99 (0.61–1.60)
Legend: ** = p < 0.001
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driver for engaging in chemsex also among our respon-
dents was a type of sex that would be impossible when
sober: Great sex that Evan’s [36] informants described as
‘fireworks’. Similar to Pollard and colleagues [11] and in-
formed by a psychodynamic perspective, also Evan [36]
concluded that other major drivers of chemsex are
loneliness and low self-esteem, again pointing to the
need for more research into the mental health aspects of
chemsex.
As for implications, healthcare professionals need to
be knowledgeable about chemsex and addressing the use
of chem-drugs themselves should be part of public
health and outreach strategies given their role in the
context of mental health and HIV/STI risk behaviors.
Chemsex may have a bidirectional link with mental
health and our findings suggest that mental health assist-
ance should be among the interventions offered to men
engaging in chemsex. Presently, there appears to be no
effective biomedical interventions for chemsex [37].
However, in Canada, the vast majority of STI clinic cli-
ents indicated being comfortable addressing mental
health and substance use concerns with an STI clinic
provider [38]. In the UK, drug services tailored to gay,
bisexual and other MSM have experienced an exponen-
tial rise in attendance [18] and in Australia, there are
positive experiences with community-led, harm reduc-
tion approaches to chemsex, utilising support services
for those seeking to manage or reduce their use, health
promotion activities, peer education, and policy work
[39]. Thus, such services may provide low barrier and
sexual-minority competent care for the two overlapping
health challenges. Lastly, given our finding that men
who were unemployed had four times greater odds of
having reduced mental health, it suggests that un-
employment has a negative health impact and indicates
the need for social and health policies.
Our findings come with limitations. The current ana-
lysis with a cross-sectional study design does not allow
for causal inferences. Findings are also limited by pos-
sible measurement bias, reliance on self-reports, and
selection bias. We sampled mostly well-educated men at
only one sexual health clinic in Oslo. The findings may
not be generalisable to men not seeking such sexual
health services; there are suspicions that STI clinic sam-
ples may over-estimate substance use behaviors [4].
Whilst chemsex is more common among men living
with HIV, our multivariate analysis did not find this link,
which may be because the vast majority of our respon-
dents were HIV-negative. All of that said, the large size
of the sample suggests findings are valid, even if some
respondents misrepresented self-reports. Other strengths
of our study include the use of validated measures,
multivariate analyses, and explicit questioning of chem-
sex. A number of studies measure the use of chem-
drugs and sexual behaviors, not the use of specific
substances in order to modify sexual sessions.
Conclusions
Our study contributes new findings to the literature on
chemsex. We provide one of the first assessments dem-
onstrating that not only men who have sex with men,
but also men who have sex with women engage in
chemsex. Chemsex was somewhat more common among
MSM than non-MSM and some characteristics of the
behavior differed, such as MSM using more GHB/GBL
for chemsex. This analysis also enhances our under-
standing of the relationship between chemsex and men-
tal health, showing that men who engage in chemsex
had two times greater odds of reduced mental health,
which affected one in five men. From a prevention and
treatment perspective, ways must be found to reduce the
burden of these overlapping conditions. STI clinics and
related sexual health services may present opportune
sites for harm reducing, syndemic service integration. In
order to build on the evidence base about chemsex and
help support the development of prevention- and treat-
ment services, further investigations should seek to en-
hance our understanding of the precursors of chemsex
and what needs are being met with chemsex, and how
these are similar and different for MSM and non-MSM.
Research is also warranted into the psychosocial impacts
of chemsex and ways to keep people safe from the direct
and indirect consequences of chemsex.
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